Compass Therapeutics Is Maintained at Buy by Guggenheim
Ratings actions from Benzinga: GMT) Compass Therapeutics Price Target Cut to $4.00/Share From $8.00 by GuggenheimRatings actions from Benzinga
Ratings actions from Benzinga: GMT) Compass Therapeutics Price Target Cut to $4.00/Share From $8.00 by GuggenheimRatings actions from Benzinga